* [[Statin/ja|スタチン]]（HMG-CoA還元酵素阻害薬）は、血管疾患との関連が最も強いコレステロールであるLDLを低下させるのに特に適している。標準的な用量
...a|単クローン抗体]]である。（例：[[Evolocumab/ja|エボロクマブ]]、[[Inclisiran/ja|インクリシラン]]）これらは[[statin/ja|スタチン]]と併用される。
...
8 KB (294 words) - 10:25, 16 April 2024
...a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85.
...(e.g. [[Evolocumab]], [[Inclisiran]]) They are used in combination with [[statin]]s.
...
6 KB (772 words) - 10:25, 16 April 2024
...a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85.
...(e.g. [[Evolocumab]], [[Inclisiran]]) They are used in combination with [[statin]]s.
...
6 KB (794 words) - 10:24, 16 April 2024
=== HMG-CoA還元酵素阻害薬（[[statin/ja|スタチン]]） ===
...
19 KB (475 words) - 20:46, 13 April 2024
...demia/ja|高血中トリグリセリド]]の治療に用いられ、[[pancreatitis/ja|膵炎]]のリスクを低下させる可能性がある。一般的に[[statin/ja|スタチン]]よりも好まれず、[[:en:NHS Scotland|NHSスコットランド]]では[[heart disease/ja|心臓病]]の
...市場では、オメガ-3酸エチルエステルは単独で高トリグリセリド血症に、または混合型[[dyslipidemia/ja|脂質異常症]]の患者に対しては[[statin/ja|スタチン]]との併用が適応となっている。
...
13 KB (590 words) - 22:14, 15 April 2024
| [[Bile acid sequestrant/ja]], [[statin/ja]], [[niacin (substance)/ja|ナイアシン]]
治療には食事療法、[[fibrate/ja|フィブラート]]、ナイアシンなどがある。[[statin/ja|スタチン]]は、トリグリセリド値を低下させる場合、フィブラートよりも優れているわけではない。
...
27 KB (764 words) - 21:33, 13 April 2024
...ntermediate risk, and patients with a score less than 10% are at low risk. Statin therapy and non-pharmacological interventions are indicated in those with h
In those at intermediate risk or low risk, the use of statin therapy depends on individual patient factors such as age, cholesterol leve
...
15 KB (2,054 words) - 17:52, 13 April 2024
...ntermediate risk, and patients with a score less than 10% are at low risk. Statin therapy and non-pharmacological interventions are indicated in those with h
In those at intermediate risk or low risk, the use of statin therapy depends on individual patient factors such as age, cholesterol leve
...
16 KB (2,114 words) - 17:52, 13 April 2024
...る。[[Niacin (substance)/ja|ナイアシン]]および[[omega-3 fatty acid/ja|オメガ3脂肪酸]]ならびに[[statin/ja|スタチン]]クラスの薬物が併用されることがあり、心血管リスクの低減が必要な中等度高トリグリセリド血症ではスタチンが主な薬物治療となる。生活習慣の
...
10 KB (363 words) - 22:41, 15 April 2024
...erosclerosis|アテローム性動脈硬化性心血管疾患]]（ASCVD）を有する成人の治療において、食事療法の補助薬および最大忍容性の[[:en:statin|スタチン]]療法の適応を有している。2015年7月にFDAにより承認されたが、年間4,500～8,000ドルの費用がかかると報告されている。
...
11 KB (424 words) - 13:13, 3 January 2024
...eridemia ≥ 150 mg/dL. Further, it is often required to be used with a statin (maximally-tolerated dose).
...on (medicine)|indicated]] to reduce cardiovascular risk as an adjunct to [[statin]] therapy.
...
13 KB (1,826 words) - 22:16, 15 April 2024
| medication = [[Statin/ja]], [[antihypertensive drug/ja|血圧降下剤]], [[aspirin/ja]]
予防ガイドラインには、[[healthy diet/ja|健康的な食事]]、運動、禁煙、正常体重の維持が含まれる。確立した疾患の治療には、[[statin/ja|スタチン]]などの[[cholesterol/ja|コレステロール]]を低下させる薬物療法、[[blood pressure medicatio
...
54 KB (1,314 words) - 18:46, 7 March 2024
...eridemia ≥ 150 mg/dL. Further, it is often required to be used with a statin (maximally-tolerated dose).
...on (medicine)|indicated]] to reduce cardiovascular risk as an adjunct to [[statin]] therapy.
...
13 KB (1,886 words) - 22:15, 15 April 2024
* [[Statin/ja|スタチン]] – [[HMG-CoA reductase/ja|HMG-CoA還元酵素]]阻害薬
...
9 KB (422 words) - 17:29, 25 March 2024
...uce the risk of [[pancreatitis]]. They are generally less preferred than [[statin]]s, and use is not recommended by [[NHS Scotland]] as the evidence does not
...e indicated for hypertriglyceridemia by itself, or in combination with a [[statin]] for people with mixed [[dyslipidemia]].
...
11 KB (1,574 words) - 22:14, 15 April 2024
欧州連合（EU）では、イコサペントエチルは[[statin/ja|スタチン]]療法の補助として心血管リスクを軽減する[[Indication (medicine)/ja|効能]]である。
...
15 KB (648 words) - 22:16, 15 April 2024
...uce the risk of [[pancreatitis]]. They are generally less preferred than [[statin]]s, and use is not recommended by [[NHS Scotland]] as the evidence does not
...e indicated for hypertriglyceridemia by itself, or in combination with a [[statin]] for people with mixed [[dyslipidemia]].
...
12 KB (1,634 words) - 22:13, 15 April 2024
* [[Statin]] – [[HMG-CoA reductase]] inhibitor
...
7 KB (907 words) - 10:49, 25 March 2024
| [[Bile acid sequestrant]]s, [[statin]]s, [[niacin (substance)|niacin]]
Treatment include diet control, [[fibrate]]s and niacins. [[Statin]]s are not better than fibrates when lowering triglyceride levels.
...
22 KB (2,903 words) - 17:19, 13 April 2024
* [[Statin]] – [[HMG-CoA reductase]] inhibitor
...
7 KB (941 words) - 10:47, 25 March 2024